SCHEMBL30729648

SCHEMBL30729648

CN1C[C@H]2CN(C(=O)OC(C)(C)C)CCN2c2ncc(C(F)(F)F)cc21

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
SCN9A Q15858 1/20 0.40
HDAC6 Q9UBN7 2/20 0.40
HDAC8 Q9BY41 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 1/20 0.40
SMARCA2 P51531 1/20 0.39
SMARCA4 P51532 1/20 0.39
PBRM1 Q86U86 1/20 0.39
TIPARP Q7Z3E1 4/20 0.38
GPR119 Q8TDV5 6/20 0.38
PIK3R1 P27986 1/20 0.38
PIK3CA P42336 1/20 0.38
MAPT P10636 1/20 0.38
STS P08842 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29841730 1.00 MEN1 (0.43) MEN1KMT2ASCN9AHDAC6HDAC8
SCHEMBL29088953 1.00 MEN1 (0.43) MEN1KMT2ASCN9AHDAC6HDAC8
SCHEMBL30729626 0.92 MEN1 (0.42) MEN1KMT2ASCN9AHDAC6HDAC8
SCHEMBL24675215 0.87 TIPARP (0.42) MEN1KMT2ASCN9AHDAC6HDAC8
SCHEMBL29088888 0.86 SMN1; SMN2 (0.43) MEN1KMT2ASMN1; SMN2LMNATIPARP
SCHEMBL29841915 0.86 SMN1; SMN2 (0.43) MEN1KMT2ASMN1; SMN2LMNATIPARP
SCHEMBL26914982 0.86 SMN1; SMN2 (0.43) MEN1KMT2ASMN1; SMN2LMNATIPARP
SCHEMBL31728771 0.86 FPR2 (0.41) SCN9ASMARCA2SMARCA4PBRM1GPR119
SCHEMBL31729435 0.86 FPR2 (0.41) SCN9ASMARCA2SMARCA4PBRM1GPR119
SCHEMBL30719996 0.85 MEN1 (0.43) MEN1KMT2AHDAC6HDAC8SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166664-A1 TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2024-05-23 US disclosed
EP-4289845-A1 TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2023-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166664-A1 TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, WEE1, WEE2 MEN1 1150/4885KMT2A 2349/4885SCN9A 4671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.